Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05131425 · ClinicalTrials.gov registry record · NA
Facing Your Fears: Adolescents With ASD and Intellectual Disability
A NA study of Anxiety and Autism Spectrum Disorder, sponsored by University of Colorado, Denver.
- Active
- Registry status
- NA
- Development phase
- 73
- Enrollment target
- 2
- Study locations
NCT05131425: Active NA study of Anxiety and Autism Spectrum Disorder, sponsored by University of Colorado, Denver.
NCT05131425 is a NA study of Anxiety and Autism Spectrum Disorder that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 73 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05131425, a NA study of Anxiety and Autism Spectrum Disorder, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 73 participants
- Enrollment target
- 2
- Study locations
Study Summary
Adolescents with ASD and intellectual disability (ID) are a complex and underserved population. Approximately 50% of individuals with ASD/ID experience significant anxiety. Yet, there are very limited mental health care interventions available for this population. Addressing anxiety and building coping skills is particularly important during adolescence as coping skills can support a successful transition to adulthood and family functioning during a difficult developmental period. The current investigators adapted a cognitive behavioral treatment (CBT) manualized intervention, Facing Your Fears, for adolescents with ASD/ID (FYF:ASD/ID) and completed a pilot study with 23 teens. Preliminary results indicated significant improvements in anxiety and mood symptoms. The proposed study seeks to test whether FYF:ASD/ID is more effective in reducing anxiety than treatment-as-usual (TAU). The investigators propose a Randomized Control Trial (RCT) with 36 adolescents with ASD/ID (12-18 years) randomized to FYF: ASD/ID and 36 adolescents randomized to TAU for 14 weeks. The 36 teens randomized to TAU will then cross-over and complete FYF:ASD/ID. Evaluations will take place at Baseline, Post-Intervention, and 6-month follow-up. Teens in the TAU will have two baseline assessments prior to crossing over to FYF:ASD/ID; both groups will complete a 6-month follow-up assessment after finishing FYF:ASD/ID. There are three aims for this project: (1) examine the efficacy of FYF: ASD/ID relative to TAU in improving anxiety as measured by parent report and determine if any gains noted in the FYF:ASD/ID are maintained at 6-month follow-up; (2) examine secondary outcomes of anxiety such as how emotion regulation and problem behavior are affected by participation in FYF:ASD/ID; and (3) examine whether adolescents' independent use of CBT skills (as assessed by goal attainment ratings of prompting level required to use strategies) to manage anxiety are increased following participation in FYF
Primary Outcome
The ADIS:ASA is a semi-structured clinical interview completed with a parent that assesses anxiety diagnoses in children and adolescents with ASD. This measure provides a total number of anxiety diagnoses for a child. The interview will be administered and anxiety diagnoses recorded at the following time points: Baseline (i.e., within 6 weeks' start of the treatment or TA condition), Post treatment (i.e., within 6 weeks of the completion of the14-week treatment or TAU condition), and follow-up (
Conditions Studied
Interventions
- OTHER Treatment as Usual
- BEHAVIORAL Facing Your Fears: ASD/ID
Study Locations (2)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2025-08-31 |
| Phase | NA |
What the registry record for NCT05131425 still lists
NCT05131425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (83% lower).
The record links to 4 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual is the first listed.
NCT05131425 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05131425 about?
NCT05131425 is a clinical study titled "Facing Your Fears: Adolescents With ASD and Intellectual Disability". Adolescents with ASD and intellectual disability (ID) are a complex and underserved population. Approximately 50% of individuals with ASD/ID experience significant anxiety. Yet, there are very limited mental health care interventions available for this population. Addressing anxiety and building cop...
What is the current status of trial NCT05131425?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 73 participants. The study started on 2021-09-01. Estimated completion is 2025-08-31.
What conditions does trial NCT05131425 study?
This clinical trial studies the following conditions: Anxiety, Autism Spectrum Disorder, Intellectual Disability, Emotion Regulation.
What interventions are being tested in trial NCT05131425?
The interventions under investigation include: Treatment as Usual (OTHER), Facing Your Fears: ASD/ID (BEHAVIORAL).
Who is sponsoring clinical trial NCT05131425?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05131425 being conducted?
This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05131425's enrollment target sits among peer trials
73 209th of 364 higher than 155 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI